Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine TumorsJonathan Strosberg, Eric P. Krenning, Rachida Lebtahi et al.|New England Journal of Medicine|2017Cited by 3.2k
Gastroenteropancreatic neuroendocrine tumoursIrvin M. Modlin, Anders Sundin, Kjell Öberg et al.|The Lancet Oncology|2008Cited by 1.8k
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup>Lu-Dotatate in the Phase III NETTER-1 TrialJonathan Strosberg, Edward M. Wolin, Beth Chasen et al.|Journal of Clinical Oncology|2018Cited by 388
Somatic mutation of CDKN1B in small intestine neuroendocrine tumorsJoshua M. Francis, Matthew Meyerson, Adam Kieżun et al.|Nature Genetics|2013Cited by 374
Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumours: Well-Differentiated Colon and Rectum Tumour/CarcinomaJohn Ramage, Martyn Caplin|Neuroendocrinology|2007Cited by 107